NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00041262,Combination Chemotherapy in Treating Patients With Esophageal Cancer,https://clinicaltrials.gov/study/NCT00041262,,UNKNOWN,"RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective in treating esophageal cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who are undergoing surgery for esophageal cancer.",NO,Esophageal Cancer,DRUG: cisplatin|DRUG: epirubicin hydrochloride|DRUG: fluorouracil|PROCEDURE: conventional surgery|PROCEDURE: neoadjuvant therapy,Survival,Disease-free survival|Local control|Morbidity from surgery and chemotherapy|Quality of life,,Medical Research Council,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,1300,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,MRC-OE05|CDR0000069457|EU-20204,2004-11,,,2003-01-27,,2013-08-12,"Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, B15 2TH, United Kingdom",
